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Background: Prostate cancer incidence is rising in the United Kingdom but there is little data on whether the disease profile is
changing. To address this, we interrogated a regional cancer registry for temporal changes in presenting disease characteristics.
Methods: Prostate cancers diagnosed from 2000 to 2010 in the Anglian Cancer Network (n¼ 21 044) were analysed. Risk
groups (localised disease) were assigned based on NICE criteria. Age standardised incidence rates (IRs) were compared between
2000–2005 and 2006–2010 and plotted for yearly trends.
Results: Over the decade, overall IR increased significantly (Po0.00001), whereas metastasis rates fell (Po0.0007). For localised
disease, IR across all risk groups also increased but at different rates (Po0.00001). The most striking change was a three-fold
increase in intermediate-risk cancers. Increased IR was evident across all PSA and stage ranges but with no upward PSA or stage
shift. In contrast, IR of histological diagnosis of low-grade cancers fell over the decade, whereas intermediate and high-grade
diagnosis increased significantly (Po0.00001).
Conclusion: This study suggests evidence of a significant upward migration in intermediate and high-grade histological diagnosis
over the decade. This is most likely to be due to a change in histological reporting of diagnostic prostate biopsies. On the basis
of this data, increasing proportions of newly diagnosed cancers will be considered eligible for radical treatment, which will have an
impact on health resource planning and provision.
Prostate cancer is the leading male cancer in the United Kingdom
and a principal cause of cancer-related mortality (http://www.info.
cancerresearchuk.org/cancerstats/types/prostate/). As in many
countries, the United Kingdom has no organised screening
programme and this is unlikely to be introduced in the near
future; at least not based on the serum PSA test (Neal et al, 2009).
Instead, the diagnosis of prostate cancer in the United Kingdom is
based on selective testing and referral by primary care physicians
using the Department of Health guidelines (Department of Health.
The NHS cancer plan. London: Department of Health, 2000;
National Institute for Health and Clinical Excellence, 2005).
Referral guidelines for suspected cancer. Clinical guideline 27).
Despite the lack of screening, it is clear that the numbers of cases
diagnosed annually in the United Kingdom is rising and is set to
increase further in future years (Mistry et al, 2011). PSA-based
screening is known to detect many indolent low-risk cancers that
may not need active treatment (Schro¨der et al, 2009). Equally, there
is evidence that the numbers of men diagnosed with metastatic
disease is reduced as a result of screening (Schro¨der et al, 2009).
In contrast, there are no data on the risk profile of cancers detected
through primary care-based assessments and referrals to prostate
diagnostic clinics. In particular, there is no study that has
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investigated whether UK prostate cancer risk profiles have
remained similar or changed over time.
The risk profile of a tumour is the most important element in
deciding how a man with prostate cancer is managed. In men with
localised non-metastatic disease, risk is defined by the presenting
PSA, tumour stage and histological grade and stratified as low,
intermediate or high risk. The specific criteria are defined in the
UK National Institute for Clinical Excellence guidelines (due to be
updated in the next year) (http://www.guidance.nice.org.uk/
CG58/Guidance/pdf/English). Understanding the nature and types
of cancers diagnosed in a health system is crucial for early
detection of demographic changes in disease presentation,
planning of resource needs and the impact on delivery of clinical
services. It can also inform better targeting of populations that will
benefit from early detection and intervention. In this study, we
interrogated a UK regional cancer registry for patterns of changes
in presentation of prostate cancer over the last 10 years. Our
primary goal was to look for any evidence of changes in presenting
risk profiles of prostate cancers diagnosed across this period.
MATERIALS AND METHODS
Patient cohort. Prostate cancers (ICD10 site: C61) diagnosed in
residents of the Anglia Cancer Network area in the East of England
region between 2000 and 2010 were registered by the National
Cancer Registration Service – Eastern Office (NCRS(E)). This area
covers B2.67 million people (1.32 million male) in northern and
central Bedfordshire, Cambridgeshire, Norfolk, Peterborough
and Suffolk. Primary sources of information include electronic
and paper-based reports and clinical notes from hospitals and
pathology laboratories. Data elements recorded by NCRS(E)
include age, hospitals of diagnosis and treatment, tumour site,
morphology, TNM (fifth edition up to 2009 and seventh edition in
2010) stage and stage components, Gleason grade, and PSA. The
stage assigned to each tumour is an integrated TNM stage at
diagnosis; this assignment was made by the NCRS(E) consultant
oncologist and/or consultant histopathologist based on combined
clinical, imaging and pathological information. Recent reports have
highlighted the completeness of staging information at NCRS(E)
(Department of Health, Delivering the Cancer Reform Strategy.
Report by the Controller and Auditor General, http://www.nao.org.
uk/wp-content/uploads/2010/11/1011568.pdf). A total of 21 044 cases
were identified, of whom 19323 (91.8%) were diagnosed at one of the
main regional NHS trusts (Norfolk and Norwich, Cambridge, Ipswich,
West Suffolk, James Paget, QE King’s Lynn, Peterborough, Bedford
and Hinchingbrooke; a further 821 (3.9%) were diagnosed at one of
the eight private hospitals in the network area. The remaining 900
cases (4.3%) were diagnosed at hospitals outside the area or at hospices
or by GPs. Overall, 18 111 (86.1%) of the diagnoses were
microscopically verified, 1966 (9.3%) were diagnosed by imaging,
816 (3.9%) were clinical diagnoses and the remaining 151 (0.7%) cases
were diagnosed by data from death certificates. Analysis was done for
the whole cohort and then stratified by age:o60 years, 60–69 years,
70–79 years and 480 years. The number of men with metastasis or
localised disease was available by year and by age groups. For localised
prostate cancer (non-metastatic), cases were further divided into risk
subgroups based on the NICE guidelines criteria for PSA, grade and
stage and stratified as low, intermediate or high risk (http://
www.guidance.nice.org.uk/CG58/Guidance/pdf/English).
Statistical analysis. Annual incidence rates (IRs) per 100 000
population were calculated for overall and age specific cohorts. For
localised prostate cancer, yearly IRs of each risk group for the
whole cohort and stratified by age groups were also computed.
Overall and age-specific incidence curves were then plotted for
visual trends. The statistical test for IR change over two time
periods (2000–2005 and 2006–2010) were assessed. To compute
IRs, we summed cases and population between 2000–2005 and
2006–2010 and then calculated 5-year rates. This was done for
incidence, metastasis and for localised disease, each risk group as
well as the subcomponents of PSA, stage and histological grade.
Difference in IR ratio between the two periods, the s.e. and
confidence interval for IR were calculated using EpiBasic
software developed by Department of Public Health, Institute
for Folkesundhed, Denmark, which is available at http://www.
folkesundhed.au.dk/uddannelse/software. A significant difference
was considered when the P-valueo0.05.
RESULTS
Incidence and presentation of prostate cancer. Analysis of
overall prostate cancer IRs demonstrated a steady increase in
numbers detected over the last 10 years by nearly 40% (Figure 1).
To investigate this further, the IR in 2000–2005 and 2006–2010
were compared (Table 1). Here there was a significant increase in
IR between the two time periods (325 vs 495, Po0.00001).
In contrast, in the same periods, IR of the proportions of men
presenting with metastatic disease actually fell (58 vs 51,
P¼ 0.0007). Analysis by age groups identified that the increase
in incidence was most pronounced in men aged under 60 years
(over two-fold; Figure 2). These data corroborate the notion of an
increase in prostate cancer incidence in the UK populations.
We have observed the greatest increase in IR amongst younger
men. In contrast, presentation with metastatic disease appears to be
falling in the same cohorts over time.
Risk profiles of cancers diagnosed with non-metastatic disease.
A key aim of the study was to investigate for any changes in the
risk categorisation of localised cancers diagnosed in the last decade.
To assess this, non-metastatic cancers were risk categorised based
on the NICE criteria by Gleason grade, stage and presenting PSA.
In comparison of the first and second half of the decades, there was
a significant increase in IR across all risk groups albeit at different
rates (Po0.00001; Table 1; Figure 3). The most striking change
was observed in the proportions of intermediate-risk cancers where
there was a greater than three-fold overall increase in IR observed.
In contrast, low-risk cancers increased at a much more modest
rate. Analysis by age groups demonstrated that this proportional
increase in intermediate-risk disease was apparent across all age
groups, for example, four-fold in men aged p60 years and five-
fold in men aged 60–69 years (Figure 3). High-risk cancer IR were
also increased across most age groups but at a more gradual pace
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Figure 1. Incidence rate of prostate cancer in the Anglian Cancer
Network 2000–2010. .
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(three-fold in men aged o60 years and two-fold in men aged
60–69 and 70–79 years; Figure 3). There was however very little
change amongst men aged over 80 years. These results suggest that
although there has been an increase across all risk groups over the
last decade, intermediate-risk cancers are now the most common
cancer group diagnosed. To better understand the underlying basis
of this change, we next analysed each subcomponent of the risk
group attributes separately.
Changes in presenting PSA. Presentation in the three risk
definitions for PSA were compared (o10, 10–20 and
420 ngml 1). In analysis of the whole group, there was a
statistically significant increase in the rates of men presenting in all
three categories between the two time periods of 2000–2005 and
2006–2010 (Table 1). Analysis of the yearly data showed that the
Table 1. Incidence rate (IR) changes in prostate cancer diagnostic characteristic between 2000–2005 and 2006–2010
Domain IR 2000–2005 IR 2006–2010 Change s.e. 95% CI P-value Trend
Total cases 365.11 416.73 51.62 5.61 62.62 40.62 o0.00001 Increase
Metastasis 58.2 51.13  7.08 2.09  2.98  11.18 0.0007 Decrease
PSA
PSAo10 70.54 128.22 57.68 2.85 63.26 52.1 o0.00001 Increase
PSA 10–20 69.66 77.3 7.64 2.43 12.41 2.87 0.0016 Increase
PSA420 61.37 90.87 29.5 2.48 34.37 24.63 o0.00001 Increase
T-stage
T1–T2 173.81 255.68 81.87 4.17 90.05 73.69 o0.00001 Increase
T3–T4 27.77 40.72 12.95 1.67 16.22 9.69 o0.00001 Increase
Gleason grade
p6 91.51 81.35  10.16 2.63  5  15.32 0.0001 Decrease
7 65.54 143.18 77.64 2.92 83.37 71.92 o0.00001 Increase
8–10 44.53 71.86 27.33 2.17 31.6 23.07 o0.00001 Increase
Risk group
Low 38.42 46.95 8.53 1.86 12.17 4.9 o0.00001 Increase
Intermediate 63.63 115.99 52.37 2.71 57.67 47.07 o0.00001 Increase
High 99.6 133.49 33.88 3.07 39.9 27.86 o0.00001 Increase
Abbreviations: CI¼ confidence interval; PSA¼prostate-specific antigen.
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Figure 2. Incidence rate of prostate cancer stratified by age groups in
the Anglia Cancer Network 2000–2010. .
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Figure 3. Incidence rates (IR) stratified by risk group and by age group
2000–2010. .
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most dramatic increase was actually seen in the relative numbers of
new diagnosis with a PSA of o10 ngml 1 (low-risk group;
Figure 4). Here, there was a six-fold increase in IRs between 2000
and 2010. In contrast, presentation with a PSA of 10–20 ngml 1
and420 ngml 1 increased by only two- to three-fold during this
period.
Changes in stage presentation. Stage is arguably the most
unreliable of the parameters used to ascribe risk in prostate cancer
in diagnosis records. In cancer registry data, it is based on both
pathological stage and/or on clinical and imaging assessment. For
this subanalysis, stage data were simplified and dichotomised as
either T1–T2 (organ confined) or T3–T4 (locally advanced).
Analysis of the whole cohort revealed a significant increase in IR of
both groups across the two time periods: T1–T2 IR 174 vs 256
(Po0.00001), T3–T4 IR 27 vs 40 (Po0.00001; Table 1). Notably,
the relative proportions of men who were organ confined and
locally advanced in both time periods, however, were very similar
suggesting that there has not been a significant shift to detection of
more organ-confined disease over the decade. Analysis of the
yearly data similarly showed a parallel increase in presentations
with both T1–T2 and T3–T4 disease between 2000 and 2010,
supporting the notion of a lack of stage shift between these two
periods (Figure 5).
Changes in grade presentation. We finally assessed for changes
in the histological diagnosis rate of low, intermediate and high-
grade tumours across the cohort. In analysis of the whole group,
there was a striking shift in grade attribution over time. Low-grade
cancers in particular were the most common type in the early years
of the decade but intermediate-grade cancers became the
predominant type in the latter half of the decade (Figure 6). In
analysis of the two time periods, there was a significant reduction
in the IR of low-grade cancers (91 vs 81, Po0.0001). In contrast,
both intermediate- and high-grade cancers had apparently
increased over the decade: intermediate-grade IR 65 vs 143
(Po0.00001), high-grade IR 44 vs 72 (Po0.00001; Table 1). We
further assessed changes in histological grade based on analysis of
the yearly data across different age groups (Figure 6). Here, we
again observed a clear increase in intermediate-grade cancers
across all age groups (Figure 6). High-grade cancers also increased
across all age groups albeit at a slower rate (Figure 6). Low-grade
cancer IR however remained stable or fell across the age groups
(Figure 6). These data suggest that there has been a significant
change in grade attribution of prostate cancer in the last decade.
Notably, a relative reduction in the numbers of low-grade cancers
diagnosed and a significant increase in the proportions of
intermediate- and high-grade cancers diagnosed. Intermediate-
grade cancers now represent the majority of new histological
diagnosis in the most contemporary series.
DISCUSSION
In a previous UK population study, Brewster et al (2000) identified
increases in cancer IRs of nearly two-fold from 1981 to 1996.
Initially, because of an increase in transurethral resection of the
prostate for obstructive symptoms and later because of an increase
in PSA testing. Data from the present study would suggest that this
rate of increase in detection is being maintained and is in line with
the projected increases over the next 20 years (Mistry et al, 2011).
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2000–2010. .
350 T1–T2
T3–T4
300
250
200
150
100
In
ci
de
nc
e 
pe
r 1
00
00
0
50
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Figure 5. Incidence rate of presentation with either organ confined
(T1–T2) or locally advanced (T3–T4) tumours 2000–2010. .
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Figure 6. Incidence rates (IR) stratified by Gleason grade and by age
group 2000–2010. .
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The protect study has highlighted the even greater incidence of
prostate cancer should a PSA-based screening test be introduced in
the United Kingdom (Moore et al, 2009). In a comparative study
with a similar population from the East of England, it was
projected that PSA screening in men aged 50–69 years would
increase the detection of prostate cancer from 130 to 2660 new
diagnosis per 100 000 population. The principal disadvantage of
such an approach, however, would be over diagnosis of low-risk
and indolent cancers (Moore et al, 2009). PSA-based screening for
prostate cancer is therefore unlikely to be adopted in the United
Kingdom in the near future.
The key factor in localised prostate cancer management is the
risk category of the disease diagnosed. A recent study from two
hospitals based in the East of England has reported that the
majority of localised cancers detected from primary care referrals
were of intermediate- or high-risk type (Serag et al, 2012). Indeed,
this has now been verified in this present study where only a
minority of contemporary cancers were categorised as low risk.
What is striking, however, is that the IRs of men classified as
having intermediate- and high-risk disease has been increasing,
whereas that of low-risk disease has been relatively stable over the
last 10 years. To our knowledge, this is the first study to report the
observation of an upward shift in risk status in a UK population-
based study. A change in the TNM classification system
(fifth edition to seventh edition) is unlikely to be the cause for
this, as it was only introduced into the registry in 2010. This
increase in intermediate- and high-risk disease has paradoxically
occurred despite a steep increase in the relative proportions of men
diagnosed at PSA levels of o10 ngml 1. Referrals from GPs are
guided by the Department of Health guidelines for cancer referrals
first formulated in 2000 and then further updated in 2005
(Department of Health. The NHS cancer plan; National Institute
for Health and Clinical Excellence. Referral guidelines for
suspected cancer. Clinical guideline 27). Importantly, however,
the criteria for raised PSA referrals were the same in both versions
(that is, age-specific PSA). Hence, there has not been a change in
recommendations for PSA thresholds for referral. Local network
guidelines similarly have not been significantly altered to our
knowledge. We hypothesise therefore that the observed change in
presenting PSA levels is probably due to a greater awareness of
prostate cancer and uptake of opportunistic testing, which has
driven both the overall rise in diagnostic rates and increased
detection at lower PSA levels.
The primary reason for the observed change in risk-group IRs
was a significant increase in the numbers of histological Gleason
sum 7 cancers and a relative fall in Gleason sum 6 cancers. Another
clear observation in this study was a relative fall in numbers of men
presenting with metastatic disease, which is consistent with other
recent population-based studies (Adolfsson et al, 2007). In these
studies, however, a decrease in metastatic rates is commonly
associated with an increase in diagnoses of Grade 6 and more
organ-confined tumours. In contrast, in our study we have
observed a paradoxical upward grade migration and no change
in clinical stages despite falling metastasis rates. One other study
has reported recent data on grade presentation in the United
Kingdom. Shafique et al (2012) in an elegant study reported on the
relationship between socioeconomic status and grade presentation
in a Scottish population from 1991 to 2007. In that study, however,
risk groups were not used and the low-grade definition included
any tumour of Gleason score p7, and hence it could not
differentiate between Gleason sum 6 and 7 tumours.
The increase in grade calling in this report is unlikely to be due
to a true increase in disease aggressiveness. Instead, it is most likely
to be a result of a change in the pathological interpretation of
diagnostic biopsies. Several reports from the United States have
similarly found an apparent upward grade migration towards more
intermediate and high-grade disease as a result of changes in
reporting practice, although ours is the first to document this
phenomenon in the United Kingdom (Derweesh et al, 2004; Jang
et al, 2006; Falzarano and Magi-Galluzzi, 2011). This in turn may
be in part due to the updating of the Gleason scoring system, which
was reviewed in 2005 (Epstein et al, 2005). Indeed, in this study the
two time periods selected (2000–2005 and 2006–2010) allow for a
convenient comparison of histological interpretation before and
after this review. Our results provide strong support for the notion
that this review may have materially changed the histological
classification of prostate cancers in the United Kingdom and
resulted in upward grade migration. Ideally, we would have liked to
review the pathology of slides before 2005 using current
pathological criteria but this was outside the scope of the present
cohort study. In a recent US paper, however, Dong et al (2012) did
apply the revised scoring system to a historical cohort of Gleason
sum 6 tumours from radical prostatectomy samples and found that
34% of patients were upgraded to Gleason sum 7 or 8 by the new
criteria. Moreover, the reclassification more accurately predicted
the subsequent behaviour of the tumours in terms of biochemical
relapse and disease progression. These and other studies highlight
the key importance of the pathologist in ascribing risk classification
and its subsequent impact on deciding a patient’s treatment as well
as outcome. Ascribing an intermediate or high Gleason sum score
will usually trigger a recommendation for active (radical) treatment
as opposed to surveillance alone by clinicians and multidisciplinary
teams managing men with prostate cancer.
An increase in the proportions of men diagnosed with disease
eligible for active treatment has significant implications for the
clinical provision of prostate cancer services. It is already recognised
that the numbers of men receiving radical therapy for localised
prostate cancer have increased dramatically in the United Kingdom
(Vesey et al, 2012). If the trends in this study are reflected nationally,
then this increase is not only driven by an overall increase in
incidence but also by more cancers being considered eligible for
therapy by virtue of being categorised as intermediate or high risk.
The use of enhanced biopsy methods (for example, extended
transrectal biopsies and template perineal biopsies) as well as
advanced imaging (for example, functional MRI) is also increasing
and the impact of this on diagnosis rates and disease presentation is
unknown (Lawrence et al, 2012; Nelson et al, 2013). The rising costs
of cancer care are increasingly being noted worldwide. In the United
States, it is projected that in the next 10 years, cancer care costs will
rise by 425% with the largest increase in spending attributed to
prostate cancer (Mariotto et al, 2011). Currently, the United
Kingdom spends the least per patient on prostate cancer compared
with other European counterpart countries (Fourcade et al, 2010).
Given the trends observed in this study and the projected national
increase in diagnosis rates, it is likely that the United Kingdom and
NHS will need to see per capita spending on prostate cancer therapy
increase dramatically in the future.
This report has a number of limitations inherent in a study
reliant on cancer registry data. Most importantly, the data
are based on the accuracy of the recorded information kept in
the National Cancer Registration Service. There was no central
review of histology and, as mentioned, stage data were based on a
combination of radiological, clinical or pathological data. Of note,
however, only a minority of men would have had pathology-based
staging from radical prostatectomy. We cannot comment on any
differences in symptomatic presentation for this cohort as these
data are not collected routinely by the registry. However, we are
not aware of any material change to the local referral guidelines
with regards symptoms within the study time frame. Finally,
we fully acknowledge that 1 of 28 cancer networks and as such our
findings may not be reflective of national practice. However, we
have no reason to suspect that the patterns observed in this region
would be outliers in terms of the approach and methods of prostate
cancer detection and diagnosis.
Changing presentation of prostate cancer in a UK population BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.589 2119
In conclusion, this study confirms increasing rates of prostate
cancer diagnosis in a UK population. Although presentation with
metastatic disease is falling, we report for the first time that there is
a paradoxical increase in the relative proportions of men classified
as having intermediate- and high-risk localised cancers. We further
observe that the critical contributory factor is likely to be a change
in histological reporting of prostate cancer biopsies rather than a
true change in diseases aggressiveness. However, further work is
needed to explore this notion and to verify the observations in
other cancer networks. In particular, we would propose a focused
study looking at pathological interpretation of diagnostic biopsies
before and after 2005 with cohort studies undertaking centralised
histology review. Nevertheless, the current data suggest a
significant change in the presenting disease profile of prostate
cancer in the United Kingdom, and this will need considering
when planning prostate cancer treatment resources especially in
the context of a centrally funded national health system.
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